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Abstract
Purpose—Menstrual pain is associated with increased production of inflammatory molecules, 
such as prostaglandins. Inflammation is involved in pathogenesis of several cancers, including 
ovarian cancer. In this study we examined the association between menstrual pain and risk of 
ovarian cancer.
Methods—We conducted a case-control study with 2028 cases of epithelial ovarian cancer, and 
2091 age and study center matched controls. Women were asked to report the severity of 
menstrual pain during their 20s and 30s, when not using oral contraceptives or breastfeeding. We 
used unconditional logistic regression to evaluate the association between menstrual pain and 
epithelial ovarian cancer risk overall, and polytomous logistic regression to evaluate whether the 
association differed across tumor subtypes.
Results—Risk of ovarian cancer was increased in women with moderate (OR=1.22, 95% CI: 
1.05–1.42) and severe pain (OR = 1.34, 95% CI: 1.09–1.65) compared to women with no or mild 
pain during menstrual period. The association differed by histologic subtypes, with significant 
associations for severe pain with endometrioid (OR = 1.64, 95% CI: 1.15–2.34) and clear cell 
tumors (OR = 1.91, 95% CI: 1.11–3.28).
Conclusions—Our data suggest that moderate and severe pain during menstrual period is 
associated with increased risk of epithelial ovarian cancer. Due to high prevalence of menstrual 
pain in women of reproductive age this observation warrants further studies.
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Introduction
Ovarian cancer is the most lethal of all gynecological cancers [1]; however the etiology is 
poorly understood. While repeated damage and repair associated with ovulation, excessive 
gonadotropin levels, or elevated androgen and progesterone explain some risk factor 
associations (e.g., parity, oral contraceptive (OC) use)[2–4], other known risk factors such as 
tubal ligation, endometriosis, and use of genital powder [5–9] likely act through other 
pathways such as inflammation [10].
Menstrual pain (dysmenorrhea) is a dull, cramping pain of varying intensity in the lower 
abdomen or pelvis [11], likely is caused by inflammatory processes. While secondary 
dysmenorrhea can be a consequence of pathological conditions such as endometriosis or 
pelvic inflammatory disease, primary dysmenorrhea occurs in the absence of known 
pathological conditions [12] and is thought to be caused by prostaglandins synthesized 
before menstruation, leading to increased uterine contractility and pain [13–17]. Higher 
levels of leukotrienes in dysmenorrheic women also may exacerbate uterine contractions 
[16, 18, 19]. Prostaglandins and leukotrienes are potent mediators of inflammation, and are 
involved in etiology of many diseases, including some cancers [20–24].
Previously, we observed a non-significant increase in risk with moderate or severe pain in 
563 cases and 523 controls [25] in the New England case control study. Here we extend this 
analysis in greater detail with over 2000 cases to assess the potential association between 
menstrual pain and ovarian cancer, and we consider the associations by tumor 
characteristics.
Methods
Study population
Enrollment of cases and controls, including selection criteria and participation rates, in the 
New England case-control (NECC) study has been described previously [26, 27]. NECC 
occurred in five phases between 1978 and 2008; data from the first two phases were 
excluded from this analysis since information about menstrual pain was either not available 
or was assessed in a way not comparable with subsequent phases. Phases included in this 
study were NECC3 (1992–1997), NECC4 (1998–2003) and NECC5 (2003–2008). During 
these phases, 3957 cases were recruited in Eastern Massachusetts and New Hampshire 
through statewide registries and tumor boards. Of these cases, 3083 (78%) met eligibility 
criteria and 2203 (71%) were enrolled; this analysis is restricted to 2041 cases with 
epithelial tumors, excluding mixed mesothelial tumors. In NECC3, 420 (72%) eligible 
controls identified through random-digit dialing agreed to participate, while 102 (51%) 
controls identified from town resident lists participated. In NECC4 and NECC5, out of 4366 
potential controls identified through drivers’ license list (NH) and town residents list (MA), 
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2940 (67%) were eligible and 1578 (54%) agreed to participate. Controls were frequency 
matched to the cases based on age and the state of residence. For this analysis we excluded 
22 women (13 cases and 9 controls) with missing information on menstrual pain, leading to 
a final number of 2028 cases and 2091 controls. Study participants underwent in-person 
interviews where detailed information was obtained on their lifestyle and reproductive 
factors, body size, medical history and family history of ovarian and breast cancer. This 
study was approved by the Institutional Review Board at Brigham and Women’s Hospital 
(Boston, MA) and the Geisel School of Medicine at Dartmouth (Hanover, NH). All 
participants provided an informed consent.
Assessment of exposure, outcome and covariates
Participants were asked to describe menstrual pain during their 20s and 30s when not using 
birth control pills (NECC3), or in their 20s and 30s when not pregnant, breastfeeding or 
using birth control pills (NECC4 and NECC5). They could choose among four options: no 
pain, mild cramps with medication seldom needed, moderate cramps with medications 
usually needed, and severe cramps with medications and bed-rest required. Women with no 
or mild pain were grouped and used as reference category.
Information on tumor histologic subtype was obtained from pathology reports and reviewed 
by a gynecological pathologist. Tumors were classified by behavior (borderline or invasive) 
and histology (serous, mucinous, endometrioid and clear cell). The following covariates 
were assessed and used in the analysis: age (continuous), age at menarche (continuous), age 
at menopause (continuous), duration of breastfeeding (continuous), age at first birth 
(continuous), age at first pregnancy (continuous), study center (Massachusetts or New 
Hampshire), history of tubal ligation (yes or no), genital powder use (yes or no), parity (0, 1, 
2, 3, 4 or more live born children), history of oral contraceptive (OC) use (< 3 months, 3 
months – 1 year, > 1 – 5 years, > 5 years), family history of ovarian and/or breast cancer 
(yes or no), infertility (yes or no), BMI (<23, 23–25, >25–30, >30), menopausal status (pre 
or post), and endometriosis (yes or no). Information on endometriosis was obtained from 
questions about a history of endometriosis, infertility due to endometriosis and reason for 
hysterectomy (all phases), reason for ovarian surgery (NECC4, NECC5), and reason for 
pelvic surgery (NECC5). The use of non-steroidal anti-inflammatory drugs (NSAIDs) for 
menstrual pain was assessed in NECC4 and NECC5, and classified as “yes” if participant 
reported usually taking prescription or over-the counter pain relievers containing aspirin or 
ibuprofen for menstrual pain or any other menstrual symptoms.
Data analysis
Unconditional logistic regression was used to estimate the odds ratios (ORs) and 95% 
confidence intervals (95% CIs) for association between menstrual pain and ovarian cancer 
risk. In the multivariate model we adjusted for matching factors (age, study center) and 
known ovarian cancer risk factors (OC use, parity, tubal ligation and family history of 
ovarian or breast cancer). We then evaluated other potential confounders by adding them 
individually to the multivariate model (endometriosis, NSAID use, age at menarche, age at 
menopause, duration of breastfeeding, age at first birth, age at first pregnancy, genital 
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powder use, BMI and menopausal status). Only covariates that changed the association 
>10% were included in the final multivariate model.
We assessed whether the association was modified by tubal ligation (yes or no), OC use (<3 
months and ≥3 months), NSAID use for menstrual pain (yes or no) and menopausal status 
(pre or postmenopausal). We used likelihood ratio tests to compare models with and without 
interaction terms to test for interactions.
Polytomous logistic regression (PLR) [28] was used to simultaneously estimate OR and 
95% CIs for ovarian cancer risk across tumor subtypes defined by behavior or histology 
(high-grade serous, low-grade serous, endometrioid, clear cell, mucinous, other). We 
adjusted for the same covariates in the PLR model as we did in the logistic regression 
model. In the PLR analysis, we forced covariates to have the same association with ovarian 
cancer for all histologic subtypes, except for age and parity which were allowed to vary 
based on previous analyses demonstrating the risk associated with these exposures varies by 
subtype [29, 30]. To assess heterogeneity across tumor subtypes, we used likelihood ratio 
test to compare a null model where menstrual pain was constrained to have the same 
association across case groups, to an alternative model where the association for menstrual 
pain was allowed to vary.
Logistic regression analysis was performed using SAS v9.3 (SAS Institute, Cary, NC) and 
polytomous logistic regression using Stata IC/12 (StataCorp, College Station, TX).
Results
The study population included 2028 cases and 2091 controls. Compared to controls, cases 
were less likely to have a tubal ligation (13.6 vs. 19.9%), more likely to be nulliparous (31.8 
vs. 17.7%) and to use genital powder (31.8 vs. 26.5%), and less likely to have used OC for 
longer than 3 months (52.1 vs. 63.4%) (Table 1). Endometriosis was more common among 
cases than controls (9.2 vs. 7.9%); similar results were noted for fibroids (17.1 vs. 14.5%) 
and family history of breast or ovarian cancer (18.2 vs. 15.3%). Cases were more likely to 
experience moderate (26.6 vs. 22.9%) or severe (12.7 vs. 9.5%) menstrual pain than 
controls. Among parous women, average duration of breastfeeding was longer among 
controls (8.6 months) than among cases (5.8 months). In age and center adjusted models, 
women with moderate pain had a 30% increased risk of ovarian cancer (95% CI: 1.13–1.51), 
while women with severe menstrual pain had 51% increased risk (95% CI: 1.23–1.84)(Table 
2). Similarly, in the multivariate model, we observed a positive association between 
menstrual pain and ovarian cancer risk (ptrend = 0.0007). Moderate pain was associated with 
22% increased risk (95% CI: 1.05–1.42) while severe pain was associated with a 34% 
increase (95% CI: 1.09–1.65) versus women with no/mild pain. Parity was the only 
confounder that changed the estimate of the association more than 10%. We observed a 14% 
(95% CI: 0.96–1.35) increase in risk for women with mild/moderate pain in parous, and 
63% (95% CI: 1.21–2.21) increase in nulliparous women. For severe pain, there was a 47% 
(95% CI: 1.15–1.89) increase in parous, and 26% (95% CI: 0.87–1.82) increase in 
nulliparous women. However, our ability to test for significant effect modification was 
limited by small number of nulliparous women in our analysis. Additional adjustment for all 
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the other potential confounders, including endometriosis, did not change the results (data not 
shown) and therefore they were not included in the model. Results were similar when 
excluding 563 cases from the previously published analysis [25], with 21% (95% CI: 1.02–
1.43) increased risk for ovarian cancer in women with moderate, and 44% increase (95% CI: 
1.12–1.86) for women with severe pain. In women who underwent tubal ligation there was 
no association between menstrual pain and ovarian cancer risk (p for trend = 0.62), while the 
association was significant for women with no tubal ligation (p for trend < 0.001). However, 
the difference between two strata was not statistically significant (p-interaction=0.27). We 
observed no statistically significant differences in associations by OC use, menopausal 
status at diagnosis, NSAID use for menstrual pain, or number of ovulatory cycles (p-
interaction>0.17; data not shown).
Menstrual pain was associated with increased risk of invasive (comparable OR = 1.39, 95% 
CI: 1.11–1.74), but not borderline cancers (comparable OR=1.19, 95% CI: 0.83–1.71)(p-
heterogeneity=0.69). Although not statistically significant (p for heterogeneity=0.37), there 
was suggestion of different associations across histologic subtypes of invasive ovarian 
cancer. We observed a statistically significant association for endometrioid (OR, severe vs. 
no/mild pain = 1.64, 95% CI: 1.15–2.34) and clear cell (comparable OR=1.91, 95% CI: 
1.11–3.28) subtypes, but not for serous high-grade (comparable OR = 1.25, 95% CI: 0.96–
1.64), serous low-grade (comparable OR = 0.92, 95% CI: 0.27–3.12) or mucinous tumors 
(comparable OR = 1.77, 95% CI: 0.99–3.18)(Table 2).
The risk estimates were slightly attenuated after adjustment for endometriosis within 
specific subtypes, including endometrioid (comparable OR=1.49, 95% CI: 1.04–2.14) and 
clear cell tumors (comparable OR = 1.55, 95% CI: 0.88–2.70), suggesting that endometriosis 
may explain at least part of the association between menstrual pain and these types of 
ovarian cancer.
Discussion
In this large case-control study we observed a significantly increased risk of ovarian cancer 
in women who had moderate or severe menstrual pain in their 20’s and 30’s, compared to 
those with no/mild pain. In our previous analysis, we did not observe a significant 
association between menstrual pain and ovarian cancer risk [25], but that analysis was 
limited to 563 cases. Two studies reported no association between menstrual pain and 
ovarian cancer, however, these studies were of limited size (112–558 cases) [31, 32]. A 
study of 1,576 cases in Australia-wide case-control study found a borderline association 
between painful periods and ovarian cancer, with women reporting often experiencing 
painful periods having 17% (95% CI: 0.98–1.40) increase in ovarian cancer risk [33]. 
Several other small studies showed a suggestive association between menstrual pain and 
ovarian cancer risk but were not adequately adjusted for potential confounders [34–36]. 
With 2028 cases in the analyses presented here, we had greater power of detecting a modest 
association.
Menstrual pain can be a consequence of either primary or secondary dysmenorrhea. 
Endometriosis is a frequent cause of secondary dysmenorrhea [37], and a risk factor for 
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some ovarian cancer subtypes, particularly endometrioid and clear cell [9, 33, 38]. In our 
study menstrual pain was associated with overall ovarian cancer, but significant associations 
were restricted to endometrioid and clear cell ovarian cancer. However, the number of 
mucinous and low-grade serous cases might have been too small to observe the difference. 
Adjusting for endometriosis attenuated the association of menstrual pain with the 
endometrioid and clear cell subtypes, but the relationship for endometrioid subtype 
remained significant, suggesting an association between menstrual pain and ovarian cancer 
independent of endometriosis. Since diagnosis of endometriosis is confirmed only by 
laparoscopy, there likely is some amount of misclassification in self-reported endometriosis 
[39], leaving the potential for residual confounding and overestimation of the association. 
We found no confounding by self-reported diagnosis of fibroids, another potential source of 
secondary dysmenorrhea. We had no information on other conditions leading to secondary 
dysmenorrhea.
Primary dysmenorrhea is associated with increased levels of inflammation during menstrual 
bleeding. Prostaglandin levels in menstrual blood are 2–4 fold higher in dysmenorrheic than 
non-dysmenorrheic women [14, 40, 41]. Some studies suggest that severity of primary 
dysmenorrhea is proportional to the prostaglandin concentration in menstrual blood [42]. 
Levels of several other inflammatory molecules such as leukotrienes and platelet-activating 
factors also have been implicated in dysmenorrhea, and are correlated with both severity and 
occurrence [16, 19]. High levels of both prostaglandins and leukotrienes reflect high levels 
of inflammation, and have been observed in several cancers [43–45]. Inflammatory 
molecules in menstrual blood could reach fallopian tubes and ovaries through retrograde 
menstruation that occurs in 76–90% of women with unobstructed fallopian tubes [46–48]. 
They could perhaps act synergistically with inflammation already occurring as a 
consequence of ovarian epithelium disruption caused by ovulation [49, 50]. Consistent with 
this hypothesis, menstrual pain was not clearly associated with ovarian cancer risk in women 
who had tubal ligation that prevents retrograde menstruation, while there was a linear trend 
in women who had not undergone tubal ligation. However, this difference was not 
statistically significant, most likely due to a small number of women with both tubal ligation 
and severe pain.
Due to the retrospective nature of this study, there was potential for recall bias of menstrual 
pain. However, recall bias would not explain suggestively different association with 
menstrual pain across histological subtypes. We were not able to separate secondary from 
primary dysmenorrhea due to a lack of information on conditions leading to secondary 
dysmenorrhea, other than endometriosis and fibroids which were self-reported. Strengths of 
our study include its large sample size of invasive epithelial cases and detailed covariate 
data allowing controlling for potential confounders.
Conclusion
In summary, our results show that compared to no or mild menstrual pain, moderate and 
severe pain are associated with increased risk of epithelial ovarian cancer, in particular for 
endometrioid and clear cell tumors. Even though ovarian cancer is a relatively rare 
malignancy, dysmenorrhea is a highly common complaint, with 16–91% of women of 
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reproductive age being affected [51]. Therefore, even a modest association would have 
important public health implications. Further investigation of this association in independent 
populations and in prospective studies is critical. Together with other known risk factors, it 
could help identify women who are at high risk that would benefit from more frequent 
screening.
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Table 1
Descriptive characteristics of invasive ovarian cancer cases and controls
Characteristics Cases (n = 2028) Controls (n = 2091)
Mean (SD)
Age (years) 52.5 (12.1) 52.4 (12.5)
Age at menarche (years) 12.6 (1.5) 12.7 (1.6)
Age at menopause (years) 49.3 (5.1) 49.5 (4.8)
Age at first pregnancya (years) 24.6 (4.9) 25.3 (5.1)
Duration of breastfeedinga (months) 5.8 (11.5) 8.6 (5.1)
Body mass index (kg/m2) 26.5 (6.3) 26.1 (5.6)
Study center, n (%)
 Massachusetts 1611 (79.4) 1700 (81.3)
 New Hampshire 417 (20.6) 391 (18.7)
History of tubal ligation, n (%)
 no 1753 (86.4) 1673 (80.0)
 yes 275(13.6) 418 (19.9)
Parity (number of children), n (%)
 0 644 (31.8) 371 (17.7)
 1 290 (14.3) 267 (12.8)
 2 536 (26.4) 665 (31.8)
 3 320 (15.8) 417 (19.9)
 ≥4 238 (11.7) 371 (17.7)
Months of oral contraceptives, n (%)
 <3 972 (47.9) 765 (36.6)
 3–12 194 (9.6) 160 (7.7)
 12–60 466 (22.9) 541 (25.9)
 >60 396 (19.5) 625 (29.9)
Menopause, n (%)
 no 889 (43.8) 924 (44.2)
 yes 1139 (56.2) 1167 (55.8)
Number of ovulatory cyclesb, n (%)
 <366 733 (36.1) 961 (45.9)
 ≥366 1135 (56.1) 962 (46.0)
Use of genital powder (%)
 no 1383 (68.2) 1536 (73.5)
 yes 645 (31.8) 555 (26.5)
History of endometriosis, n (%)
 no 1841 (90.8) 1926 (92.1)
 yes 187 (9.2) 165 (7.9)
Infertility, n (%)
 no 1641 (80.9) 1697 (81.2)
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Characteristics Cases (n = 2028) Controls (n = 2091)
 yes 387 (19.1) 394 (18.8)
Fibroids, n (%)
 no 1681 (82.9) 1787 (85.5)
 yes 347 (17.1) 304 (14.5)
Family history of breast or ovarian cancer, n (%)
 no 1659 (81.8) 1770 (84.7)
 yes 369 (18.2) 321 (15.3)
Menstrual pain, n (%)
 no pain 451 (22.2) 492 (23.5)
 mild 779 (38.4) 922 (44.1)
 moderate 540 (26.6) 479 (22.9)
 severe 258 (12.7) 198 (9.5)
aAmong parous women
b
Percents don’t sum to 100 due to missing observations for 160 cases and 168 controls
Cancer Causes Control. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Babic et al. Page 12
Ta
bl
e 
2
O
dd
s r
at
io
s (
OR
) a
nd
 95
% 
co
nfi
de
nc
e i
nte
rva
ls 
(C
I) 
for
 th
e a
sso
cia
tio
n b
etw
ee
n m
en
str
ua
l p
ain
 an
d o
ve
ral
l o
r h
ist
olo
gic
al 
su
bty
pe
-sp
ec
ifi
c r
isk
 of
 
in
va
siv
e 
ov
ar
ia
n 
ca
nc
er
.
C
as
es
 N
 (%
)
C
on
tr
ol
s N
 (%
)
O
ve
ra
ll 
(n
=2
02
8) 
O
R
 (9
5%
 C
I)b
En
do
m
et
ri
oi
d 
(n
 = 
32
9) 
OR
 (9
5%
 C
I) 
d
C
le
ar
 ce
ll 
(n
 = 
11
6) 
O
R
 (9
5%
 C
I)d
Se
ro
us
 h
ig
h-
gr
ad
e (
n 
=
 8
93
) O
R 
(95
%
 C
I) 
d
Se
ro
us
 lo
w
-g
ra
de
 
(n
=3
3) 
OR
 (9
5%
 
C
I) 
d
M
uc
in
ou
s i
nv
as
iv
e 
(n
=9
2) 
OR
 (9
5%
 
C
I)d
N
o 
or
 m
ild
 p
ai
n
12
30
 (6
0.7
)
14
14
 (6
7.6
)
1.
00
 (r
ef)
1.
00
 (r
ef)
1.
00
 (r
ef)
1.
00
 (r
ef)
1.
00
 (r
ef)
1.
00
 (r
ef)
M
od
er
at
e 
pa
in
54
0 
(26
.6)
47
9 
(22
.9)
1.
22
 (1
.05
–1
.42
)
1.
37
 (1
.04
–1
.81
)
1.
61
 (1
.04
–2
.49
)
1.
17
 (0
.96
–1
.42
)
1.
04
 (0
.46
–2
.36
)
0.
85
 (0
.49
–1
.46
)
Se
ve
re
 p
ai
n
25
8 
(12
.7)
19
8 
(9.
5)
1.
34
 (1
.09
–1
.65
)
1.
64
 (1
.15
–2
.34
)
1.
91
 (1
.11
–3
.28
)
1.
25
 (0
.96
–1
.64
)
0.
92
 (0
.27
–3
.12
)
1.
77
 (0
.99
–3
.18
)
P 
fo
r t
re
nd
c
0.
00
07
0.
00
2
0.
00
6
0.
03
9
0.
94
7
0.
17 P h
et
er
og
en
ei
ty
e 
=
 0
.3
7
a
Pa
rti
ci
pa
nt
s w
er
e 
fre
qu
en
cy
 m
at
ch
ed
 o
n 
ag
e 
an
d 
stu
dy
 c
en
te
r
b A
dju
ste
d f
or 
ag
e, 
stu
dy
 ce
nte
r, p
ari
ty,
 O
C 
use
, tu
ba
l li
ga
tio
n a
nd
 fa
mi
ly 
his
tor
y o
f o
va
ria
n o
r b
rea
st 
can
cer
c P
-v
al
ue
 fo
r t
re
nd
 w
as
 o
bt
ai
ne
d 
us
in
g 
or
di
na
l c
at
eg
or
ie
s f
or
 m
en
str
ua
l p
ai
n
d A
dju
ste
d f
or 
ag
e, 
stu
dy
 ce
nte
r, p
ari
ty,
 O
C 
use
, tu
ba
l li
ga
tio
n a
nd
 fa
mi
ly 
his
tor
y o
f o
va
ria
n o
r b
rea
st 
can
cer
 in
 th
e p
oly
tom
ou
s l
og
ist
ic 
reg
res
sio
n m
od
el
e P
-v
al
ue
 fo
r h
et
er
og
en
ei
ty
 w
as
 o
bt
ai
ne
d 
us
in
g 
lik
el
ih
oo
d 
ra
tio
 te
st
Cancer Causes Control. Author manuscript; available in PMC 2015 December 01.
